GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (LTS:0A5V) » Definitions » Cyclically Adjusted PB Ratio

Viatris (LTS:0A5V) Cyclically Adjusted PB Ratio : 0.47 (As of May. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Viatris Cyclically Adjusted PB Ratio?

As of today (2024-05-22), Viatris's current share price is $10.9925. Viatris's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $23.38. Viatris's Cyclically Adjusted PB Ratio for today is 0.47.

The historical rank and industry rank for Viatris's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0A5V' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.38   Med: 2.13   Max: 8.54
Current: 0.47

During the past years, Viatris's highest Cyclically Adjusted PB Ratio was 8.54. The lowest was 0.38. And the median was 2.13.

LTS:0A5V's Cyclically Adjusted PB Ratio is ranked better than
87.83% of 674 companies
in the Drug Manufacturers industry
Industry Median: 1.855 vs LTS:0A5V: 0.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Viatris's adjusted book value per share data for the three months ended in Mar. 2024 was $16.813. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $23.38 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viatris Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Viatris's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Cyclically Adjusted PB Ratio Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.22 1.05 0.69 0.52 0.47

Viatris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.44 0.43 0.47 0.51

Competitive Comparison of Viatris's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PB Ratio falls into.



Viatris Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Viatris's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=10.9925/23.38
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Viatris's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=16.813/131.7762*131.7762
=16.813

Current CPI (Mar. 2024) = 131.7762.

Viatris Quarterly Data

Book Value per Share CPI Adj_Book
201406 8.915 100.560 11.682
201409 9.054 100.428 11.880
201412 8.677 99.070 11.542
201503 18.536 99.621 24.519
201506 19.465 100.684 25.476
201509 19.957 100.392 26.196
201512 19.902 99.792 26.281
201603 20.908 100.470 27.423
201606 20.318 101.688 26.330
201609 22.104 101.861 28.596
201612 20.765 101.863 26.863
201703 21.749 102.862 27.863
201706 23.937 103.349 30.521
201709 24.782 104.136 31.360
201712 25.386 104.011 32.163
201803 25.567 105.290 31.999
201806 23.682 106.317 29.353
201809 23.402 106.507 28.954
201812 23.589 105.998 29.326
201903 23.026 107.251 28.292
201906 23.074 108.070 28.136
201909 22.210 108.329 27.017
201912 23.024 108.420 27.984
202003 21.787 108.902 26.363
202006 22.722 108.767 27.529
202009 24.273 109.815 29.127
202012 19.019 109.897 22.806
202103 17.720 111.754 20.895
202106 17.538 114.631 20.161
202109 17.481 115.734 19.904
202112 16.943 117.630 18.981
202203 16.867 121.301 18.324
202206 16.335 125.017 17.218
202209 15.818 125.227 16.645
202212 17.361 125.222 18.270
202303 17.151 127.348 17.747
202306 17.382 128.729 17.793
202309 17.393 129.860 17.650
202312 17.045 129.419 17.355
202403 16.813 131.776 16.813

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viatris  (LTS:0A5V) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Viatris Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Viatris's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris (LTS:0A5V) Business Description

Industry
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (LTS:0A5V) Headlines

No Headlines